Want to see GB:BVXP full AI Analyst Report?
BVXP Stock Chart & Stats
1525.00 p
-35.00 p(-2.30%)
At close: 4:00 PM EDT
1525.00 p
-35.00 p(-2.30%)
Day’s Range― - ―
52-Week Range1,300.00 p - 2,550.00 p
Previous CloseN/A
Volume13.43K
Average Volume (3M)7.85K
Market Cap
£78.37M
Enterprise Value95.58 p
Total Cash (Recent Filing)£5.30M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)10.6
Beta0.65
Next Earnings
Oct 26, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend Yield10%
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.94
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetZero reported debt and an equity-funded structure materially reduce refinancing and liquidity risk. Combined with very high returns on equity (mid-50% to ~70%), the capital structure supports durable dividend capacity, downside protection and strategic optionality over the next several months.
Exceptional Profitability And MarginsSustained very high gross and net margins reflect unique product performance and pricing power in high-affinity monoclonal antibodies. These margins create durable earnings power, funding operating investment and shareholder returns even if revenue growth temporarily softens.
High-quality Cash ConversionNear-1.0 cash conversion means reported profits reliably translate to free cash flow, supporting dividends, buybacks, and selective reinvestment. This strong cash generation underpins financial resilience and long-term capital allocation flexibility despite short-term revenue swings.
Bears Say
Recent Slowdown In Revenue And FCFA measurable drop in 2025 revenue and free cash flow signals weakening operating momentum. For a company whose income depends on recurring test volumes, prolonged soft demand could compress investment capacity and pressure future royalty growth, making near-term earnings less predictable.
Customer And Revenue Concentration RiskRevenue depends on a limited set of diagnostics customers and the commercial success of assays that embed Bioventix antibodies. If a major customer discontinues an assay or sales fall, royalty-linked annuity streams can decline materially, creating persistent downside risk to top-line stability.
Geographic/market Exposure And Limited ScaleDocumented market pressure in China and a disclosed 2025 earnings decline highlight exposure to regional demand shifts. With a very small team and drifting equity/assets, the company may struggle to rapidly diversify customers or geographies, making recovery and scaling slower.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1300.00 p and its highest was 2550.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £78.37M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Oct 26, 2026 which is in 74 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Mar 30, 2026. The company reported 0.684 p earnings per share for the quarter, beating the consensus estimate of 0.511 p by 0.173 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 70 p which represents an annual dividend yield of 10%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate is 0.66.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.684 p in its last earnings report, beating expectations of 0.511 p. Following the earnings report the stock price went up 6.909%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
10.00%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―